盐酸吡格列酮治疗2型糖尿病68例的疗效观察

目的:观察盐酸吡格列酮对68例2型糖尿病患者各代谢相关指标的影响及临床疗效。方法:选择2008年3月～2010年2月在我院门诊或住院诊治的2型糖尿病患者136例,将其随机分为观察组和对照组各68例。对照组予以格列吡嗪控释片5mg,用温开水整片吞服,1次/d;观察组在对照组基础上加服盐酸吡格列酮30mg,早餐后口服,1次/d;两组患者疗程均为12周,同时均要求饮食控制和体育锻炼以改善血糖控制。结果:两组治疗后SBP,DBP,HbA1c,FBG,Fins,TG,LDL-C及HOMA-IR指标与治疗前比较均有统计学意义(P<0.05或P<0.01);治疗后,观察组SBP,DBP,HbA1c,FBG,Fins,TG,LDL-C及HOMA-IR指标与对照组比较差异有统计学意义(P<0.05或P<0.01)。结论:在2型糖尿病患者中,早期予以格列吡嗪控释片治疗基础上应用盐酸吡格列酮,不仅可以使患者血糖降低、血压降低、调脂,还可以减轻高胰岛素血症,使胰岛素抵抗得到改善,进而改善与其相关的各种代谢异常。

Observations on the Efficacy of Pioglitazone Hydrochloride in Treating 68 Cases of T2DM

Objective:Observe the pioglitazone hydrochloride therapy’s influences on metabolism-related indexes in 68 T2DM cases and its clinical efficacy.Methods:136 T2DM cases diagnosed in the out-patient or in-patient department of our hospital,between March 2008 and February 2010,were randomly divided into an observation group and a control group,each containing 68 cases.The control group took Glipizide Controlled-Release Tablet(5 mg qd po)with warm water(boiled),the tablet was to be swallowed as a whote;while the observation group took the same glipizide medication together win pioglitazone hydrochloride(30 mg qd pj)by mouth.The treating period of the two groups were all 12 weeks,meanwhile both groups were requested to maintain diet and workout in order to improve glycemic control.Results:The two groups’ SBP,DBP,HbA1c,FBG,Fi ns,TG,LDL-C and HOMA-IR levels before and after treatments indicated significant differences respectively(P<0.05 or P<0.01),and variations of SBP,DBP,HbA1c,FBG,Fins,TG,LDL-C and HOMA-IR levels after treatments between the control group and the observation group had significant differences as well(P<0.05 or P<0.01).Conclusion:Therapy of pioglitazone hydrochloride on the basis of Glipizide Controlled-Release Tablets’ treatment during the early stage of T2DM,not only reduced the glycemic level,blood pressure as well as restoring blood lipids,but also alleviated hyperinsulinemia and insulin-resistance,which in turn ameliorated all kinds of related metabolic disorders.